Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment

Davenport, Elizabeth S.; Arnett, Stephanie; Nichols, Molly A.; Miller, Monica L.

doi:10.1016/j.japh.2020.01.001

Cited by 22 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there may be more providers, pharmacy staff can knowingly or unwittingly present barriers to buprenorphine access, with some pharmacists limiting buprenorphine access based on perceived “DEA caps”, concern for misuse/ diversion, buprenorphine knowledge gaps, stigmatizing attitudes toward opioid use disorder (OUD) treatment, and mistrust between pharmacists and physicians. 6 , 7 , 8 , 9 , 10 , 11 A secret shopper study of 704 pharmacies in urban Texas found that only 42.2% of pharmacies were willing to dispense a 1-week supply of generic suboxone, a buprenorphine product. 12 Among the pharmacies studied, 45% of chain pharmacies versus 12% of independent pharmacies were willing to dispense a 1- week supply of Suboxone®.…”

Section: Introductionmentioning

confidence: 99%

Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia

Trull

Major

Harless

et al. 2021

Exploratory Research in Clinical and Social Pharmacy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia

Trull

Major

Harless

et al. 2021

Exploratory Research in Clinical and Social Pharmacy

View full text Add to dashboard Cite

“…As evidenced by studies evaluating pharmacists' perceptions of buprenorphine prescribing, stigma may have influenced the findings of this study. This may include a lack of fundamental knowledge regarding MOUD, pharmacists' concerns regarding the diversion potential of such medications, as well as diminished trust between pharmacists and physicians due to perceived overprescribing of opioids and fear of DEA investigation due to opioid ordering thresholds [15,30]. Review of the literature regarding this topic has demonstrated a correlation between advanced training in MOUD with increased confidence and improved counseling when treating patients with OUD [31].…”

Section: Discussionmentioning

confidence: 99%

Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey

Syros

Rodriguez

Rennick

et al. 2022

Addict Sci Clin Pract

View full text Add to dashboard Cite

Background Despite the proven efficacy of medications for opioid use disorder (MOUD) and recent reduction in barriers to prescribers, numerous obstacles exist for patients seeking MOUD. Prior studies have used telephone surveys to investigate pharmacy-related barriers to MOUD. We applied this methodology to evaluate inpatient and outpatient pharmacy barriers to MOUD in South Florida. Methods Randomly selected pharmacies in South Florida (Miami-Dade, Broward, and Palm Beach Counties) were called using a standardized script with a “secret shopper” approach until 200 successful surveys had been completed. The primary outcome was the availability of any buprenorphine products. Second, a list of all 48 acute care hospitals within the aforementioned counties was compiled, and hospitals were contacted by telephone using a second structured script. Results A total of 1374 outpatient pharmacies and 48 inpatient pharmacies were identified. 378 randomly selected outpatient pharmacies were contacted to accrue 200 successful calls (53% success rate). All 48 inpatient pharmacies were contacted to successfully complete 25 inpatient surveys (52%). Of the 200 outpatient pharmacies contacted, 38% had any buprenorphine available. There was a significant difference in buprenorphine availability by county, with Miami-Dade having the least availability and Palm Beach having the most availability (27% vs. 47%, respectively; p = 0.04). Of the 38% with buprenorphine available, 82% had a sufficient supply for a two-week prescription of buprenorphine 8 mg twice daily. Of the pharmacies that did not have buprenorphine, 55% would be willing to order with a median estimated time to receive an order of 2 days (IQR 1.25–3 days). Of the 25 surveyed inpatient pharmacies, 88% reported having buprenorphine on inpatient formulary, and 55% of hospitals had at least one restriction on ordering of buprenorphine beyond federal regulations. Conclusions The results of this study highlight significant pharmacy-related barriers to comprehensive OUD treatment across the healthcare system including both acute care hospital pharmacies and outpatient community pharmacies. Despite efforts to increase the number of MOUD providers, there still remain downstream obstacles to MOUD access.

show abstract

“…18 A nonvalidated survey revealed knowledge deficits regarding MOUD medications among pharmacist preceptors (n = 85). 37 Despite limitations of small sample and one state, the findings emphasize the need for pharmacists to examine their attitudes toward MOUD and update their knowledge on the etiology of OUD. 19 Targeted education addressing misconceptions regarding OUD may reduce stigma to improve care.…”

Section: Barriers To Pharmacists Providing Care To Patients With Oudmentioning

confidence: 90%

“…36 Examples of stigmatizing actions include pharmacists denying access to MOUD when presented with a legitimate prescription, viewing MOUD as "substituting one addiction for another," or simply neglecting to offer professional services to patients who have an OUD diagnosis. 37 As hospitals and clinics are focused on treating patients with COVID-19, care for patients with OUD who are currently stigmatized by health care systems may be overlooked. 18 A nonvalidated survey revealed knowledge deficits regarding MOUD medications among pharmacist preceptors (n = 85).…”

Section: Barriers To Pharmacists Providing Care To Patients With Oudmentioning

confidence: 99%

Pharmacists and opioid use disorder care during COVID‐19: Call for action

Mohammad

Berri

Lehr

2021

J Am Coll Clin Pharm

View full text Add to dashboard Cite

Opioid use disorder (OUD) is a chronic relapsing condition characterized by problematic opioid use causing significant impairment in daily life. Medication for opioid use disorder using buprenorphine, methadone, and naltrexone with behavioral therapy reduces illicit opioid use and risk of overdose death. Despite evidence and decades of experience, barriers limit access to treatment and care for individuals with OUD.Barriers include a lack of treatment centers particularly in rural areas, regulations on buprenorphine prescribing, and stigma from the community and health care professionals. While many barriers are longstanding, the coronavirus disease 2019 (COVID-19) pandemic-forced isolation and associated stress has exacerbated challenges for individuals with mental health conditions such as OUD. Pharmacists are wellpositioned to bridge existing gaps in OUD care, particularly during the COVID-19 pandemic. Roles for pharmacists include OUD risk identification and screening, referral of patients to treatment and support programs, ensuring medication access, expanding naloxone access, and advocacy initiatives. This review article identifies barriers to care for patients with OUD during the COVID-19 pandemic and explores opportunities and resources for pharmacists to improve OUD care during the pandemic and beyond.

show abstract

Indiana community pharmacist preceptors’ knowledge and perceptions of medication-assisted treatment

Cited by 22 publications

References 19 publications

Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia

Rural community pharmacist willingness to dispense Suboxone® - A secret shopper investigation in South-Central Appalachia

Availability of medications for opioid use disorder in outpatient and inpatient pharmacies in South Florida: a secret shopper survey

Pharmacists and opioid use disorder care during COVID‐19: Call for action

Contact Info

Product

Resources

About